Related Experiment Video
Updated: Mar 18, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.4K
Summary
Most hypertension patients in the US stop treatment within 5 years. Improved patient education on disease, treatment, and outcomes can significantly reduce this high dropout rate.
Area of Science:
- Cardiovascular Medicine
- Public Health
Background:
- Recent studies indicate a significant 5-year treatment abandonment rate among hypertensive patients in the United States.
- This high dropout rate is not attributed to adverse effects of prescribed therapies.
Purpose of the Study:
- To investigate the primary reasons for treatment non-adherence in hypertensive patients.
- To identify strategies for improving long-term patient engagement in hypertension management.
Main Methods:
- Analysis of data from two recent publications on patient adherence.
- Qualitative assessment of patient-reported reasons for discontinuing treatment.
Main Results:
- The majority of hypertensive patients abandon treatment within 5 years.
- Patients frequently cited lack of adequate information regarding their condition and treatment protocols as the main reason for cessation.
- Side effects were not identified as a primary cause for abandonment.
Conclusions:
- Enhancing patient and family understanding of hypertension, treatment plans, expected results, and potential side effects is crucial.
- Improved patient education is a key strategy to markedly decrease treatment dropout rates in hypertension management.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
821
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
821
01:16Antihypertensive Drugs: Action of Diuretics
2.7K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.7K
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
2.6K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.6K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
536
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
536
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
3.0K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K